Mesa Laboratories Inc. MLAB
Industrial Machinery/Components · data as of November 13, 2026
Mesa Laboratories Inc. (MLAB) is a industrial company listed in the US with a market value of about $781M. In the twelve months to September 30, 2026 it had revenue of $251M and net income of $7M, a net margin of 2.7%.
Its overall Stock Analiz score is 2.4 out of 5 (weak). The strongest part is financial health (4/5); the weakest is value (1/5).
Key numbers: a P/E of 120.9, a price to free cash flow of 15.8, 5-year revenue growth of 13% a year, a 5-year average ROIC of -13%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 37% below the current price.
About Mesa Laboratories
Mesa Laboratories is listed in the US and classified in industrial machinery/components. Revenue went from $71M in 2015 to $249M in 2026, growth of about 12.0% a year. It was profitable in 7 of the last 10 years in our data. Its share count rose by 4% over three years (dilution for shareholders). It spends 8% of revenue on research and development.
Score: 2.4 / 5
Checks passed
- P/FCF below 20
- Profit margin improving
- 3-year free cash flow growth above 10% a year
- Strong R&D investment or growth above 20%
- 5-year EPS growth above 10% a year
- 5-year revenue growth above 8% a year
- More cash than debt, or low debt to equity
- Positive free cash flow
Checks not passed
- P/E below 25
- P/E below the industry median
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- 5-year average ROIC above 12%
- Profitable 5 years in a row
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $251M | $249M | $241M | $216M | $219M | $184M | $134M | $118M | $103M | $96M | $94M |
| Net income | $7M | $7M | -$2M | -$254M | $930000 | $2M | $3M | $2M | $7M | -$3M | $11M |
| Free cash flow | $49M | $40M | $43M | $42M | $23M | $35M | $35M | $25M | $29M | $23M | $6M |
| EPS (diluted) | $1.15 | $1.21 | $-0.36 | $-47.20 | $0.17 | $0.35 | $0.64 | $0.41 | $1.86 | $-0.79 | $2.91 |
| Net margin | 2.7% | 2.7% | -0.8% | -117.6% | 0.4% | 1.0% | 2.4% | 1.5% | 7.3% | -3.1% | 11.9% |
| ROIC | — | 3.8% | 5.2% | -76.9% | 0.5% | 0.4% | 1.8% | 1.7% | 6.3% | 0.0% | 8.3% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 1 analysts is $150.00, 8% above the current price; targets range from $150.00 to $150.00; the consensus rating is “Buy”; expected EPS is $11.52 for the fiscal year ending March 31, 2027.
Frequently asked questions
What is Mesa Laboratories’s P/E ratio?
About 120.9, based on the last twelve months of diluted earnings per share (forward P/E about 12.3).
Is Mesa Laboratories stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 37% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Mesa Laboratories pay a dividend?
Yes. The dividend yield is about 0.46%, and it has paid dividends for 10 years in our data.
Is Mesa Laboratories a good stock to buy?
We do not give buy or sell advice. Mesa Laboratories scores 2.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.